Prana Biotechnology’s PBT2 Trial Provides Further Data On Treating Alzheimer’s Disease

Prana Biotechnology’s PBT2 Trial Provides Further Data On Treating Alzheimer’s Disease
Recent results from Prana Biotechnology’s IMAGINE Alzheimer’s trial, released earlier this year (March), as well as the company’s ongoing sub-analysis, has suggested to the company’s research team that further analysis of the PiB-PET Standardized Uptake Value Ratio (SUVR) and the tendency towards preservation of brain volume in PBT2 treated patients may be necessary. The results of the ongoing analysis will allow

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *